[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371142-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371142-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","new-progress-and-challenges-of-targeted-therapies-for-breast-cancer-mini-review","New progress and challenges of targeted therapies for breast cancer - Mini-review","","Breast cancer, a heterogeneous malignancy with a significant global burden, necessitates evolving therapeutic strategies. With nearly two million new cases diagnosed annually, metastatic dissemination remains a critical clinical challenge despite progress in surgery, radiotherapy, and cytotoxic chemotherapy. Targeted therapies—including monoclonal antibodies, small-molecule inhibitors, and antibody-drug conjugates—selectively modulate oncogenic signaling to inhibit tumor growth and spread, aiming to reduce systemic toxicities. Clinical benefits are shown across subtypes, while resistance and toxicity limit outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/new-progress-and-challenges-of-targeted-therapies-for-breast-cancer-mini-review/371142/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/new-progress-and-challenges-of-targeted-therapies-for-breast-cancer-mini-review/371142.png","ImageObject",300,407,{"name":42,"@type":43},"moss~","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What targeted therapy options are discussed for breast cancer?","Question",{"text":63,"@type":64},"The text highlights monoclonal antibodies, small-molecule inhibitors, and antibody-drug conjugates (ADCs). It also mentions pathway-focused agents such as HER2-targeted therapies and inhibitors of CDK4/6, PARP, and PI3K.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do targeted therapies aim to improve breast cancer management?",{"text":68,"@type":64},"They selectively inhibit oncogenic signaling pathways that drive tumor proliferation, survival, and immune evasion. This strategy is described as potentially reducing systemic toxicities compared with broader approaches.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges still limit the effectiveness of targeted therapies?",{"text":72,"@type":64},"Acquired resistance is emphasized, often driven by pathway reactivation or gene mutations. The text also notes treatment-related toxicities and the need for robust predictive biomarkers to refine patient selection.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371142,1790789285,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Ann Palliat Med. Author manuscript; available in PMC 2026 August 12. |\n| --- | --- |\n\nPublished in final edited form as:  \nAnn Palliat Med. 2025 July ; 14(4): 345–352. doi:10.21037/apm-25-30 .  \nNew progress and challenges of targeted therapies for breast cancer  \nBoyu Wang 1 , Xingyu He2 , Suchandrima Dutta2 , Sophie Chen2 , Jialiang Liang2 , Wei Huang3 , Waqas Ahmad2 , Meifeng Xu2 , Yigang Wang2  \n1 Department of Internal Medicine, Sutter Medical Center-Sacramento, Roseville, CA, USA  \n2 Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA  \n3 Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA  \nAbstract  \nBreast cancer, a heterogeneous malignancy with a significant global burden, necessitates evolving therapeutic strategies. With nearly two million new cases diagnosed annually, metastatic dissemination remains a critical clinical challenge despite advancements in surgery, radiotherapy, and cytotoxic chemotherapy. The emergence of targeted therapies, including monoclonal antibodies, small-molecule inhibitors, and antibody-drug conjugates (ADCs), has revolutionized breast cancer management by selectively modulating oncogenic signaling pathways to inhibit tumor proliferation and spread. This approach offers a more focused treatment strategy with the potential for reduced systemic toxicities. Targeted therapies have demonstrated significant clinical efficacy across breast cancer subtypes. For instance, agents such as trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1) improved survival in human epidermal growth factor receptor 2 (HER2)-positive disease. Similarly, cyclin dependent kinase 4/6 (CDK4/6) and poly (ADP-ribose) polymerase (PARP) inhibitors have yielded substantial benefits in hormone receptor-positive and breast cancer gene (BRCA)-mutated breast cancers, respectively, by modulating endocrine resistance and DNA repair pathways. Furthermore, phosphoinositide 3-kinase (PI3K) inhibitors for PIK3CA-mutant tumors and immune checkpoint inhibitors for triple-negative breast cancer (TNBC) have expanded the available therapeutic measures. However, despite these advancements, challenges such as acquired resistance, often driven by pathway reactivation or gene mutations,  \nOpen Access Statement: This is an Open Access article distributed in accordance with the Creative Commons AttributionNonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: [https://creativecommons.org/licenses/](https://creativecommons.org/licenses/)[ ](https://creativecommons.org/licenses/)[by-nc-nd/4.0/](by-nc-nd/4.0/.)[.](by-nc-nd/4.0/.)  \nCorrespondence to: Yigang Wang, MD, PhD, FAHA. Director of Regenerative Medicine Research, Professor, Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, PO Box 670529, Cincinnati, OH 45267-0529, [USA. yigang.wang@uc.edu](USA. yigang.wang@uc.edu).  \nContributions: (I) Conception and design: Y Wang; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: B Wang, X He, S Dutta, S Chen, J Liang; (V) Data analysis and interpretation: B Wang, X He, S Chen, J Liang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \nPeer Review File: Available at [https://apm.amegroups.com/article/view/10.21037/apm-25-30/prf](https://apm.amegroups.com/article/view/10.21037/apm-25-30/prf)  \nEthical Statement: The authors are accountable for all aspects of the wor","cbCaiaf76BwPIolV","https://ap.wps.com/l/cbCaiaf76BwPIolV","pdf",67654,"English","# Abstract\n# Keywords\n# Introduction\n## Targeted therapy paradigm shift\n# Open Access Statement","[{\"question\":\"What targeted therapy options are discussed for breast cancer?\",\"answer\":\"The text highlights monoclonal antibodies, small-molecule inhibitors, and antibody-drug conjugates (ADCs). It also mentions pathway-focused agents such as HER2-targeted therapies and inhibitors of CDK4/6, PARP, and PI3K.\"},{\"question\":\"How do targeted therapies aim to improve breast cancer management?\",\"answer\":\"They selectively inhibit oncogenic signaling pathways that drive tumor proliferation, survival, and immune evasion. This strategy is described as potentially reducing systemic toxicities compared with broader approaches.\"},{\"question\":\"What challenges still limit the effectiveness of targeted therapies?\",\"answer\":\"Acquired resistance is emphasized, often driven by pathway reactivation or gene mutations. The text also notes treatment-related toxicities and the need for robust predictive biomarkers to refine patient selection.\"}]","New progress and challenges of targeted therapies for breast cancer - Mini-review | PDF",1790191341,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da316d7d73495d070b42dac611e4b39e.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8bfcafb7e42c883e63350912bb182464.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d38479a3de4800847a5dc0bab0164b9a.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7e7165c4bc48a77bd37425e11027856.webp",980,1268]